Concepts (162)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Angiopoietin-2 | 1 | 2020 | 125 | 0.77 | Why? |
| Enbucrilate | 1 | 2018 | 7 | 0.76 | Why? |
| Sclerotherapy | 1 | 2018 | 23 | 0.75 | Why? |
| Capnography | 1 | 2017 | 32 | 0.67 | Why? |
| Esophageal and Gastric Varices | 1 | 2018 | 117 | 0.64 | Why? |
| Foramen Ovale, Patent | 1 | 2018 | 153 | 0.60 | Why? |
| Cerebral Infarction | 1 | 2018 | 245 | 0.58 | Why? |
| Endothelium, Vascular | 5 | 2021 | 1751 | 0.52 | Why? |
| Carbon Dioxide | 2 | 2017 | 917 | 0.50 | Why? |
| Respiration Disorders | 1 | 2017 | 526 | 0.44 | Why? |
| Diaphragm | 1 | 2011 | 232 | 0.37 | Why? |
| von Willebrand Factor | 4 | 2021 | 668 | 0.35 | Why? |
| Ventilator Weaning | 1 | 2011 | 536 | 0.32 | Why? |
| Heart, Artificial | 1 | 2020 | 35 | 0.22 | Why? |
| E-Selectin | 1 | 2020 | 55 | 0.21 | Why? |
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2020 | 66 | 0.21 | Why? |
| Myelopoiesis | 1 | 2021 | 116 | 0.21 | Why? |
| Antigens, CD19 | 1 | 2020 | 98 | 0.21 | Why? |
| Intensive Care Units | 6 | 2021 | 29594 | 0.21 | Why? |
| Vascular Endothelial Growth Factor A | 2 | 2021 | 604 | 0.20 | Why? |
| Endothelial Progenitor Cells | 1 | 2020 | 103 | 0.20 | Why? |
| Renal Tubular Transport, Inborn Errors | 1 | 2018 | 6 | 0.19 | Why? |
| Hypercalciuria | 1 | 2018 | 8 | 0.19 | Why? |
| Nephrocalcinosis | 1 | 2018 | 14 | 0.19 | Why? |
| Lupus Coagulation Inhibitor | 1 | 2021 | 262 | 0.19 | Why? |
| Thrombopoiesis | 1 | 2018 | 39 | 0.18 | Why? |
| Cellular Microenvironment | 1 | 2018 | 55 | 0.18 | Why? |
| Hyperoxia | 1 | 2018 | 51 | 0.18 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2017 | 5002 | 0.18 | Why? |
| Neovascularization, Pathologic | 1 | 2021 | 305 | 0.17 | Why? |
| ADAMTS13 Protein | 1 | 2021 | 363 | 0.17 | Why? |
| Anticoagulants | 4 | 2021 | 9563 | 0.15 | Why? |
| Pulmonary Circulation | 1 | 2018 | 207 | 0.15 | Why? |
| Megakaryocytes | 1 | 2018 | 274 | 0.15 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 1 | 2021 | 520 | 0.15 | Why? |
| Magnesium | 1 | 2018 | 290 | 0.15 | Why? |
| France | 9 | 2021 | 12074 | 0.14 | Why? |
| Venous Thromboembolism | 3 | 2021 | 4273 | 0.13 | Why? |
| Hospital Mortality | 8 | 2021 | 22087 | 0.13 | Why? |
| Biomarkers | 7 | 2021 | 23361 | 0.13 | Why? |
| Fibrin Fibrinogen Degradation Products | 4 | 2021 | 5993 | 0.12 | Why? |
| Tracheotomy | 1 | 2018 | 427 | 0.12 | Why? |
| Paris | 3 | 2021 | 1287 | 0.12 | Why? |
| Thrombophilia | 2 | 2021 | 1935 | 0.11 | Why? |
| Prospective Studies | 9 | 2021 | 43301 | 0.11 | Why? |
| Thrombosis | 3 | 2021 | 7504 | 0.10 | Why? |
| Obesity | 2 | 2021 | 7388 | 0.10 | Why? |
| Respiratory Function Tests | 1 | 2017 | 1755 | 0.10 | Why? |
| Multiple Organ Failure | 1 | 2020 | 1724 | 0.10 | Why? |
| Pneumonia, Bacterial | 1 | 2017 | 843 | 0.10 | Why? |
| Patient Admission | 3 | 2021 | 5250 | 0.10 | Why? |
| Gene Expression Profiling | 1 | 2020 | 3788 | 0.09 | Why? |
| Male | 20 | 2021 | 367725 | 0.09 | Why? |
| Thromboembolism | 1 | 2021 | 2101 | 0.09 | Why? |
| Gene Expression Regulation | 1 | 2020 | 4020 | 0.09 | Why? |
| Kaplan-Meier Estimate | 3 | 2021 | 4260 | 0.08 | Why? |
| International Cooperation | 1 | 2020 | 3436 | 0.08 | Why? |
| Aged | 15 | 2021 | 215776 | 0.08 | Why? |
| Middle Aged | 17 | 2021 | 270681 | 0.08 | Why? |
| Liver | 1 | 2021 | 4007 | 0.08 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2021 | 5277 | 0.08 | Why? |
| Hospitalization | 7 | 2021 | 54280 | 0.08 | Why? |
| Severity of Illness Index | 8 | 2021 | 48226 | 0.08 | Why? |
| Renin-Angiotensin System | 1 | 2021 | 3661 | 0.07 | Why? |
| Critical Care | 2 | 2020 | 14081 | 0.07 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.07 | Why? |
| Proportional Hazards Models | 3 | 2021 | 6543 | 0.07 | Why? |
| Humans | 26 | 2021 | 930598 | 0.07 | Why? |
| Female | 16 | 2021 | 380317 | 0.06 | Why? |
| Fibroblast Growth Factor 2 | 1 | 2021 | 77 | 0.06 | Why? |
| Pulmonary Embolism | 1 | 2020 | 4775 | 0.05 | Why? |
| Sepsis | 1 | 2018 | 3517 | 0.05 | Why? |
| Placenta Growth Factor | 1 | 2021 | 93 | 0.05 | Why? |
| Molecular Weight | 1 | 2021 | 249 | 0.05 | Why? |
| Endothelial Cells | 2 | 2021 | 2048 | 0.05 | Why? |
| Collagen | 1 | 2021 | 222 | 0.05 | Why? |
| Pulmonary Disease, Chronic Obstructive | 1 | 2017 | 3832 | 0.05 | Why? |
| Tachycardia | 1 | 2020 | 239 | 0.05 | Why? |
| Polyploidy | 1 | 2018 | 16 | 0.05 | Why? |
| Hemorheology | 1 | 2018 | 17 | 0.05 | Why? |
| Cytokines | 1 | 2021 | 15010 | 0.05 | Why? |
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2018 | 18 | 0.05 | Why? |
| Simplified Acute Physiology Score | 1 | 2018 | 102 | 0.05 | Why? |
| ROC Curve | 2 | 2021 | 6024 | 0.04 | Why? |
| Respiration, Artificial | 2 | 2020 | 22116 | 0.04 | Why? |
| Systemic Inflammatory Response Syndrome | 1 | 2018 | 6653 | 0.04 | Why? |
| Body Mass Index | 2 | 2021 | 4306 | 0.04 | Why? |
| Blood Coagulation | 2 | 2021 | 2768 | 0.04 | Why? |
| Early Medical Intervention | 1 | 2021 | 487 | 0.04 | Why? |
| Th2 Cells | 1 | 2020 | 680 | 0.04 | Why? |
| Cohort Studies | 4 | 2021 | 36005 | 0.04 | Why? |
| Diuretics | 1 | 2018 | 326 | 0.04 | Why? |
| Human Umbilical Vein Endothelial Cells | 1 | 2018 | 286 | 0.04 | Why? |
| Cell Separation | 1 | 2018 | 270 | 0.04 | Why? |
| T-Lymphocytes, Cytotoxic | 1 | 2020 | 552 | 0.04 | Why? |
| Chest Pain | 1 | 2020 | 578 | 0.04 | Why? |
| Patients' Rooms | 1 | 2021 | 675 | 0.04 | Why? |
| Interleukin-1beta | 1 | 2021 | 992 | 0.04 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.04 | Why? |
| Ultrasonography | 1 | 2011 | 4409 | 0.04 | Why? |
| Chi-Square Distribution | 1 | 2018 | 961 | 0.04 | Why? |
| Statistics, Nonparametric | 1 | 2018 | 1008 | 0.04 | Why? |
| Chemokines | 1 | 2021 | 1095 | 0.04 | Why? |
| Protein Multimerization | 1 | 2021 | 1336 | 0.04 | Why? |
| Protective Factors | 1 | 2021 | 1720 | 0.03 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| Th1 Cells | 1 | 2020 | 1228 | 0.03 | Why? |
| Hemostasis | 1 | 2020 | 811 | 0.03 | Why? |
| Area Under Curve | 1 | 2021 | 2564 | 0.03 | Why? |
| Prevalence | 3 | 2020 | 25773 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2020 | 2437 | 0.03 | Why? |
| Proton Pump Inhibitors | 1 | 2018 | 377 | 0.03 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.03 | Why? |
| Prognosis | 3 | 2021 | 32490 | 0.03 | Why? |
| Propensity Score | 1 | 2021 | 2690 | 0.03 | Why? |
| Cooperative Behavior | 1 | 2020 | 1216 | 0.03 | Why? |
| Lung | 1 | 2021 | 31049 | 0.03 | Why? |
| Combined Modality Therapy | 1 | 2020 | 3395 | 0.03 | Why? |
| Retrospective Studies | 5 | 2021 | 105322 | 0.03 | Why? |
| Pulmonary Artery | 1 | 2018 | 803 | 0.03 | Why? |
| Precision Medicine | 1 | 2021 | 1477 | 0.03 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.03 | Why? |
| Membrane Proteins | 1 | 2021 | 1733 | 0.03 | Why? |
| Fatal Outcome | 1 | 2020 | 3438 | 0.03 | Why? |
| Lymphocyte Activation | 1 | 2020 | 2742 | 0.03 | Why? |
| Computed Tomography Angiography | 1 | 2020 | 2153 | 0.03 | Why? |
| Proteomics | 1 | 2020 | 2481 | 0.02 | Why? |
| Adaptive Immunity | 1 | 2021 | 2585 | 0.02 | Why? |
| Odds Ratio | 1 | 2020 | 5861 | 0.02 | Why? |
| Adult | 6 | 2021 | 244371 | 0.02 | Why? |
| Transcriptome | 1 | 2021 | 3466 | 0.02 | Why? |
| Electronic Health Records | 1 | 2021 | 3492 | 0.02 | Why? |
| Risk Factors | 3 | 2021 | 71621 | 0.02 | Why? |
| Survival Rate | 1 | 2021 | 9206 | 0.02 | Why? |
| Blood Coagulation Disorders | 1 | 2020 | 2040 | 0.02 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| Patient Selection | 1 | 2020 | 4560 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2018 | 2844 | 0.02 | Why? |
| Survival Analysis | 1 | 2018 | 7592 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2020 | 9893 | 0.02 | Why? |
| Protein Binding | 1 | 2021 | 11430 | 0.02 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.02 | Why? |
| Tomography, X-Ray Computed | 2 | 2020 | 25144 | 0.02 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.02 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.02 | Why? |
| Interleukin-6 | 1 | 2021 | 7522 | 0.02 | Why? |
| Case-Control Studies | 1 | 2020 | 17671 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2020 | 10649 | 0.01 | Why? |
| Adolescent | 2 | 2021 | 86841 | 0.01 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.01 | Why? |
| Infant, Newborn | 1 | 2021 | 23105 | 0.01 | Why? |
| Hypertension | 1 | 2021 | 8895 | 0.01 | Why? |
| Inflammation | 1 | 2021 | 13255 | 0.01 | Why? |
| Infant | 1 | 2021 | 30274 | 0.01 | Why? |
| Child, Preschool | 1 | 2021 | 36283 | 0.01 | Why? |
| Risk Assessment | 1 | 2020 | 25439 | 0.01 | Why? |
| Cardiovascular Diseases | 1 | 2020 | 11497 | 0.01 | Why? |
| Treatment Outcome | 1 | 2020 | 51732 | 0.01 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.01 | Why? |
| Child | 1 | 2021 | 70012 | 0.01 | Why? |
| Antiviral Agents | 1 | 2021 | 41703 | 0.01 | Why? |
Diehl's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(162)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(290)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_